

Joshua A Roth

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/776100/publications.pdf>

Version: 2024-02-01

31
papers

933
citations

567281

15
h-index

454955

30
g-index

31
all docs

31
docs citations

31
times ranked

1671
citing authors

#	ARTICLE	IF	CITATIONS
1	The impact of the Oncotype Dx breast cancer assay in clinical practice: a systematic review and meta-analysis. <i>Breast Cancer Research and Treatment</i> , 2013, 141, 13-22.	2.5	198
2	A formal risk-benefit framework for genomic tests: Facilitating the appropriate translation of genomics into clinical practice. <i>Genetics in Medicine</i> , 2010, 12, 686-693.	2.4	83
3	Cost-effectiveness of axicabtagene ciloleucel for adult patients with relapsed or refractory large B-cell lymphoma in the United States. <i>Journal of Medical Economics</i> , 2018, 21, 1238-1245.	2.1	80
4	Value and affordability of CAR T-cell therapy in the United States. <i>Bone Marrow Transplantation</i> , 2020, 55, 1706-1715.	2.4	66
5	Economic Analysis of Prostate-Specific Antigen Screening and Selective Treatment Strategies. <i>JAMA Oncology</i> , 2016, 2, 890.	7.1	65
6	Prognostic Role of ERCC1 in Advanced Non-Small-Cell Lung Cancer: A Systematic Review and Meta-Analysis. <i>Clinical Lung Cancer</i> , 2011, 12, 393-401.	2.6	63
7	Economic Return From the Women's Health Initiative Estrogen Plus Progestin Clinical Trial. <i>Annals of Internal Medicine</i> , 2014, 160, 594.	3.9	53
8	A qualitative study exploring why individuals opt out of lung cancer screening. <i>Family Practice</i> , 2017, 34, cmw146.	1.9	50
9	Cost-Effectiveness of a Computerized Provider Order Entry System in Improving Medication Safety Ambulatory Care. <i>Value in Health</i> , 2014, 17, 340-349.	0.3	30
10	Projected Clinical, Resource Use, and Fiscal Impacts of Implementing Low-Dose Computed Tomography Lung Cancer Screening in Medicare. <i>Journal of Oncology Practice</i> , 2015, 11, 267-272.	2.5	23
11	A qualitative study exploring patient motivations for screening for lung cancer. <i>PLoS ONE</i> , 2018, 13, e0196758.	2.5	22
12	Alcohol misuse, genetics, and major bleeding among warfarin therapy patients in a community setting. <i>Pharmacoepidemiology and Drug Safety</i> , 2015, 24, 619-627.	1.9	20
13	Cost-Effectiveness of Gemcitabine + Cisplatin vs. Gemcitabine Monotherapy in Advanced Biliary Tract Cancer. <i>Journal of Gastrointestinal Cancer</i> , 2012, 43, 215-223.	1.3	18
14	Design of a cost-effectiveness analysis alongside a randomized trial of transplantation using umbilical cord blood versus HLA-haploidentical related bone marrow in advanced hematologic cancer. <i>Journal of Comparative Effectiveness Research</i> , 2014, 3, 135-144.	1.4	18
15	Impact of Body Mass Index and Genetics on Warfarin Major Bleeding Outcomes in a Community Setting. <i>American Journal of Medicine</i> , 2017, 130, 222-228.	1.5	18
16	Stakeholder Perspectives on a Risk-Benefit Framework for Genetic Testing. <i>Public Health Genomics</i> , 2011, 14, 59-67.	1.0	17
17	Safety and Costs of Endobronchial Ultrasound-Guided Nodal Aspiration and Mediastinoscopy. <i>Chest</i> , 2020, 157, 686-693.	0.8	15
18	Potential Cost-Effectiveness of Risk-Based Pancreatic Cancer Screening in Patients With New-Onset Diabetes. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2022, 20, 451-459.	4.9	13

#	ARTICLE	IF	CITATIONS
19	The Short-Term Cost-Effectiveness of Once-Daily Liraglutide Versus Once-Weekly Exenatide for the Treatment of Type 2 Diabetes Mellitus in the United States. PLoS ONE, 2015, 10, e0121915.	2.5	12
20	The Potential Long-Term Comparative Effectiveness of Larotrectinib and Entrectinib for Second-Line Treatment of TRK Fusion-Positive Metastatic Lung Cancer. Journal of Managed Care & Specialty Pharmacy, 2020, 26, 981-986.	0.9	9
21	Cost-Effectiveness of a 14-Gene Risk Score Assay to Target Adjuvant Chemotherapy in Early Stage Non-Squamous Non-Small Cell Lung Cancer. Oncologist, 2014, 19, 466-476.	3.7	8
22	Cost-Effectiveness of a Biopsy-Based 8-Protein Prostate Cancer Prognostic Assay to Optimize Treatment Decision Making in Gleason 3 + 3 and 3 + 4 Early Stage Prostate Cancer. Oncologist, 2015, 20, 1355-1364.	3.7	8
23	Survival Gains from First-Line Systemic Therapy in Metastatic Non-Small Cell Lung Cancer in the U.S., 1990-2015: Progress and Opportunities. Oncologist, 2017, 22, 304-310.	3.7	8
24	Intensity modulated radiation therapy following lumpectomy in early-stage breast cancer: Patterns of use and cost consequences among Medicare beneficiaries. PLoS ONE, 2019, 14, e0222904.	2.5	8
25	Clinical and Budget Impact of Increasing Colorectal Cancer Screening by Blood- and Stool-Based Testing. American Health and Drug Benefits, 2019, 12, 256-262.	0.5	7
26	The Women's Health Initiative Estrogen-alone Trial had differential disease and medical expenditure consequences across age groups. Menopause, 2020, 27, 632-639.	2.0	6
27	A comparison of mixture cure fraction models to traditional parametric survival models in estimation of the cost-effectiveness of nivolumab for relapsed small cell lung cancer. Journal of Medical Economics, 2021, 24, 79-86.	2.1	6
28	Computed Tomography Screening for Lung Cancer. JAMA - Journal of the American Medical Association, 2016, 315, 77.	7.4	4
29	Patient Knowledge and Expectations About Return of Genomic Results in a Biomarker-Driven Master Protocol Trial (SWOG S1400GEN). JCO Oncology Practice, 2021, 17, e1821-e1829.	2.9	4
30	Estimating Long-Term Survival for Patients with Relapsed or Refractory Aggressive Non-Hodgkin Lymphoma Treated with Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy: A Comparison of Standard and Mixture Cure Models. Biology of Blood and Marrow Transplantation, 2018, 24, S310.	2.0	1
31	THE AUTHORS RESPOND. Journal of Managed Care & Specialty Pharmacy, 2020, 26, 1617-1618.	0.9	0